Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	59.44	53.99	35.63	66.89	130.1	122.16
Short-Term Investments	50.75	62.88	135.93	176.64	47.5	72.08
Cash & Short-Term Investments	110.2	116.87	171.56	243.52	177.61	194.24
Cash Growth	-23.14%	-31.88%	-29.55%	37.11%	-8.56%	343.70%
Other Receivables	1.25	0.99	0.58	0.4	0.11	0.1
Receivables	1.25	0.99	0.58	0.4	0.11	0.1
Inventory	-	-	-	0.1	0.2	0.08
Prepaid Expenses	0.13	0.6	0.86	0.81	1.11	1.51
Other Current Assets	3.94	3.79	5.32	1.79	1.31	2.73
Total Current Assets	115.51	122.25	178.31	246.62	180.33	198.66
Property, Plant & Equipment	0.15	0.24	0.34	0.5	0.27	0.04
Long-Term Investments	-	-	59.97	62.55	15.84	31.62
Other Intangible Assets	0.02	0.03	0.08	-	-	-
Other Long-Term Assets	0.32	0.31	0.3	0.45	0.15	0.01
Total Assets	116.01	122.83	238.99	310.13	196.59	230.33

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	13.38	0.55	5.65	1.38	1.64	1.09
Accrued Expenses	13.55	20.36	21.6	10.51	5.94	3.86
Current Portion of Long-Term Debt	19.67	8.77	-	-	-	-
Current Portion of Leases	0.08	0.15	0.13	0.87	0.11	-
Other Current Liabilities	0.17	0.18	0.23	0.21	0.13	0.2
Total Current Liabilities	46.85	30.01	27.61	12.97	7.81	5.15
Long-Term Debt	11.9	22.4	29.42	29.9	-	-
Long-Term Leases	-	-	0.15	0.28	-	-
Total Liabilities	58.74	52.4	57.18	43.15	7.81	5.15

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0	0
Additional Paid-In Capital	557.19	516.8	506.99	489.45	359.95	352.98
Retained Earnings	-499.92	-446.46	-325.13	-222.8	-170.43	-127.57
Comprehensive Income & Other	-0.01	0.08	-0.05	0.31	-0.75	-0.23
Total Common Equity	57.26	70.43	181.82	266.97	188.78	225.18
Shareholders' Equity	57.26	70.43	181.82	266.97	188.78	225.18
Total Liabilities & Equity	116.01	122.83	238.99	310.13	196.59	230.33

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	31.65	31.31	29.7	31.05	0.11	-
Net Cash (Debt)	78.55	85.55	201.82	275.03	193.34	225.86
Net Cash Growth	-42.27%	-57.61%	-26.62%	42.25%	-14.40%	415.92%
Net Cash Per Share	1.22	1.41	3.36	5.66	4.76	11.26
Filing Date Shares Outstanding	72.32	72.21	60.57	60.08	41.03	40.47
Total Common Shares Outstanding	72.31	60.58	60.09	57.91	41.03	40.47
Working Capital	68.67	92.25	150.7	233.64	172.52	193.51
Book Value Per Share	0.79	1.16	3.03	4.61	4.60	5.56
Tangible Book Value	57.24	70.4	181.74	266.97	188.78	225.18
Tangible Book Value Per Share	0.79	1.16	3.02	4.61	4.60	5.56

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error